Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium animalis lactis is a probiotic strain that has been investigated for its potential benefits in managing symptoms of Irritable Bowel Syndrome (IBS). Several randomized controlled trials (RCTs) and meta-analyses have explored its efficacy, particularly in reducing bloating, abdominal pain, and improving bowel habits in IBS patients. Notably, a formulation containing B. animalis subsp. lactis DN-173 010 (marketed as Activia) has been studied in multiple clinical trials, with some showing modest improvements in IBS symptoms compared to placebo. A 2017 systematic review (Ford et al., American Journal of Gastroenterology) found that certain probiotics, including Bifidobacterium species, may provide a small but statistically significant benefit in global IBS symptoms and abdominal pain, though heterogeneity between studies and probiotic formulations was high.

The proposed mechanisms include modulation of gut microbiota, enhancement of intestinal barrier function, and anti-inflammatory effects. However, while there is scientific validation for its use, the overall quality of evidence is moderate, as not all studies show benefit, and study designs vary widely. Guidelines from organizations such as the American College of Gastroenterology suggest that probiotics may be considered for IBS, but do not endorse specific strains due to variability in the evidence. In summary, B. animalis lactis is supported by moderate scientific evidence for symptomatic relief in some IBS patients, but results are mixed and further high-quality research is needed.

More about Bifidobacterium animalis lactis
More about Irritable Bowel Syndrome

Other ingredients used for Irritable Bowel Syndrome

Other health conditions supported by Bifidobacterium animalis lactis

Products containing Bifidobacterium animalis lactis